Literature DB >> 7767914

Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.

J C Luo1, A I Neugut, G Garbowski, K A Forde, M Treat, S Smith, W P Carney, P W Brandt-Rauf.   

Abstract

Plasma levels of p53 protein were examined by an enzyme linked immunosorbent assay in 184 patients enrolled in a colonoscopy study. The mean levels among 47 individuals with normal colonoscopic examinations and no prior history of colonic neoplasia (0.12 ng/ml) and among 61 individuals with normal colonoscopic examinations and a prior history of colonic neoplasia (0.09 ng/ml) were similar. However, the mean levels among 54 individuals with newly diagnosed colonic adenomas (0.44 ng/ml) and 22 individuals with newly diagnosed colonic carcinomas (0.55 ng/ml) were statistically significantly elevated compared to the normal controls (P < 0.02). Among these tumor patients, the plasma levels tended to increase with increasing adenoma size and with increasing carcinoma stage, although these trends were not statistically significant. Defining a significant positive plasma level as any value greater than ten times background, the percentage of positive samples increased from 4% in the controls to 20% in the adenoma cases to 32% in the carcinoma cases. These results demonstrate that plasma p53 protein levels are elevated in a subgroup of individuals with colonic neoplasia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767914     DOI: 10.1016/0304-3835(95)03744-h

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  The molecular epidemiology of occupational carcinogenesis in vinyl chloride exposed workers.

Authors:  M J Marion; I De Vivo; S Smith; J C Luo; P W Brandt-Rauf
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

3.  Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?

Authors:  Vibhav Malviya; Harbans Singh; U S Dwivedi; P B Singh
Journal:  Urol Res       Date:  2004-10-19

4.  Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

Authors:  P W Brandt-Rauf; J M Chen; M J Marion; S J Smith; J C Luo; W Carney; M R Pincus
Journal:  J Protein Chem       Date:  1996-05

5.  p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.

Authors:  De-Qing Mu; Guo-Feng Wang; Shu-You Peng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde.

Authors:  J Shaham; Y Bomstein; R Gurvich; M Rashkovsky; Z Kaufman
Journal:  Occup Environ Med       Date:  2003-06       Impact factor: 4.402

7.  Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.

Authors:  Nobuya Daitoku; Yuji Miyamoto; Yuki Sakamoto; Ryuma Tokunaga; Yukiharu Hiyoshi; Yohei Nagai; Masaaki Iwatsuki; Shiro Iwagami; Naoya Yoshida; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2019-12-13       Impact factor: 3.402

8.  A label-free biosensor based on silver nanoparticles array for clinical detection of serum p53 in head and neck squamous cell carcinoma.

Authors:  Wei Zhou; Yingyi Ma; Huan Yang; Yi Ding; Xiangang Luo
Journal:  Int J Nanomedicine       Date:  2011-03-02

Review 9.  Biomarkers of gene expression: growth factors and oncoproteins.

Authors:  P W Brandt-Rauf
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

10.  p53 protein is absent from the serum of patients with lung cancer.

Authors:  M A Levesque; M D'Costa; E P Diamandis
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.